A Study on the Association Between Preventive Behaviors and Quality of Life in High-risk Populations for Postoperative Lymphedema Following Breast Cancer Surgery [0.03%]
乳腺癌术后肢体淋巴水肿高风险人群的预防行为与生活质量关联性研究
Chen Li,Xianhua Li,Qin Xu et al.
Chen Li et al.
Background: Postoperative lymphedema is a chronic complication that impairs quality of life (QoL) in breast cancer survivors. Preventive behaviors are key to mitigation, but their relationship with QoL in high-risk popula...
Prevalence and Prognostic Implications of Circulating Tumor Cells Among Patients Undergoing Neoadjuvant Chemotherapy for Early-Stage Breast Cancer [0.03%]
新辅助化疗早期乳腺癌患者循环肿瘤细胞的检出率及其预后意义
Mark Freeman,Alicja Prawdzic Senkowska,Rania Chehade et al.
Mark Freeman et al.
Background: Circulating tumor cells (CTCs) are frequently detected in patients with breast cancer, but key studies investigating their clinical significance in early-stage disease rely on less-sensitive methods for CTC de...
Intraoperative Indocyanine Green Angiography as a Predictor of Complications in Breast Cancer Patients Undergoing Conservative Mastectomy [0.03%]
乳房保留手术中吲哚菁绿血管造影对预测乳腺癌患者术后并发症的作用
Gianluca Vanni,Marco Pellicciaro,Marco Materazzo et al.
Gianluca Vanni et al.
Background: Conserving mastectomy techniques, such as nipple-sparing and skin-sparing mastectomy, enable immediate breast reconstruction, improving aesthetic outcomes but increasing the risk of postoperative complications...
Pharmacologic Features, Clinical Applications, and Drug Safety Evaluation of Inavolisib in the Treatment of Metastatic Breast Cancer [0.03%]
Inavolisib治疗转移性乳腺癌的药理学特征、临床应用及药物安全性评估
Vincenzo Di Lauro,Alessandro Rizzo,Paola C Sacco et al.
Vincenzo Di Lauro et al.
The clinical benefit of available treatments in metastatic hormone receptor (HR)+/HER2-breast cancer (BC) remains limited due to the onset of resistance mechanisms, hence the need for increasingly personalized therapies targeting specific m...
Survival After Multimodal Treatment for Breast Cancer in Brazil: The Predominant Role of Clinical Stage and Treatment Response [0.03%]
巴西乳腺癌多模式治疗后的生存率：临床分期和治疗反应起决定作用
Júlio Cesar Prestes,Andre Guimares Gouveia,Maurício Fraga da Silva et al.
Júlio Cesar Prestes et al.
Background: Neoadjuvant systemic therapy (NST) enables early systemic disease control and assessment of treatment response in breast cancer. Survival after NST may also be influenced by subsequent local-regional treatment...
Clinical Characteristics and Cancer Histories Among Breast Cancer Patients With Li-Fraumeni Syndrome From a Single Institution [0.03%]
单中心乳腺癌患者中李-佛美尼综合征的临床特征及癌症史
Ashley H Woodson,Aydah Al-Awadhi,Jessica Corredor et al.
Ashley H Woodson et al.
Introduction: Li-Fraumeni syndrome increases the risks of multiple cancers, including early-onset breast cancer (BC). At The University of Texas MD Anderson Cancer Center, we aimed to describe the complete cancer historie...
Methodological Concerns Regarding the Assessment of Breast Cancer Risk Following Gender-Affirming Care [0.03%]
关于性别肯定护理后乳腺癌风险评估的方法学关注点
Alison May Berner,Chloe Pasin
Alison May Berner
Despite Advances, Repeat Breast-Conserving Surgery Rates Persist: A 25-Year National Analysis of Breast-Conserving Surgery in Australia [0.03%]
尽管有所进步，澳大利亚乳腺癌保乳术后重复手术率仍然居高不下——基于澳大利亚25年的全国数据分析
Magdalena Sejka,Anita Skandarajah,Christobel Saunders
Magdalena Sejka
Using Australian Medicare Benefits Schedule data from 2000-2024, this national study examined repeat breastconserving surgery after initial excision for breast cancer. Repeat procedures remained persistently high (18.6%) despite evolving ma...
Clinicopathological Characterization of HER2-Low-Expressing Triple-Negative Breast Cancer: Distinct Features From HER2-Zero Subtype [0.03%]
HER2低表达型三阴性乳腺癌的临床病理特征：与HER2零亚型的区别
Michiko Kato,Hiroko Masuda,Sayuka Nakayama et al.
Michiko Kato et al.
Background: Triple-negative breast cancer (TNBC) is an aggressive disease characterized by a poor prognosis and marked biological heterogeneity. Recently, HER2-low tumors have emerged as potential therapeutic targets. How...
Palbociclib in Patients With HR+/HER2- Advanced or Metastatic Breast Cancer and Bone-Only Metastasis: A Systematic Literature Review [0.03%]
帕博西尼治疗HR阳性/HER2阴性晚期或转移性乳腺癌及仅有骨转移患者：系统文献回顾
Joyce O&#x;Shaughnessy,Nusrat Jahan,Anna Louise Barry et al.
Joyce O&#x;Shaughnessy et al.
Background: Bone-only metastatic breast cancer remains generally incurable and is associated with considerable morbidity and mortality. The limited data available on palbociclib treatment outcomes in patients with HR+/HER...